- Home
- SNDX vs MFA Comparison
SNDX vs MFA Comparison
Compare SNDX & MFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- MFA
- Stock Information
- Founded
- SNDX 2005
- MFA 1997
- Country
- SNDX United States
- MFA United States
- Employees
- SNDX N/A
- MFA N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- MFA Real Estate Investment Trusts
- Sector
- SNDX Health Care
- MFA Real Estate
- Exchange
- SNDX Nasdaq
- MFA Nasdaq
- Market Cap
- SNDX 1.1B
- MFA 1.0B
- IPO Year
- SNDX 2016
- MFA N/A
- Fundamental
- Price
- SNDX $9.12
- MFA $9.38
- Analyst Decision
- SNDX Strong Buy
- MFA Buy
- Analyst Count
- SNDX 11
- MFA 6
- Target Price
- SNDX $35.91
- MFA $12.50
- AVG Volume (30 Days)
- SNDX 1.8M
- MFA 1.3M
- Earning Date
- SNDX 07-31-2025
- MFA 08-07-2025
- Dividend Yield
- SNDX N/A
- MFA 15.21%
- EPS Growth
- SNDX N/A
- MFA N/A
- EPS
- SNDX N/A
- MFA 0.99
- Revenue
- SNDX $43,722,000.00
- MFA $292,245,000.00
- Revenue This Year
- SNDX $426.77
- MFA N/A
- Revenue Next Year
- SNDX $98.31
- MFA $14.73
- P/E Ratio
- SNDX N/A
- MFA $9.56
- Revenue Growth
- SNDX N/A
- MFA 52.95
- 52 Week Low
- SNDX $8.58
- MFA $7.85
- 52 Week High
- SNDX $25.07
- MFA $13.45
- Technical
- Relative Strength Index (RSI)
- SNDX 38.53
- MFA 53.45
- Support Level
- SNDX $11.00
- MFA $9.45
- Resistance Level
- SNDX $11.83
- MFA $9.66
- Average True Range (ATR)
- SNDX 0.54
- MFA 0.18
- MACD
- SNDX -0.12
- MFA 0.01
- Stochastic Oscillator
- SNDX 18.12
- MFA 63.00
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About MFA MFA Financial Inc.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.